source
- STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and moreIn a win for peptide proponents, an FDA advisory panel recommended compounding pharmacies be allowed to make four of the drugsSTAT · 7d ago↗ source
- Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effectsA new analysis of patients who took part in clinical trials for Kite Pharma’s CAR-T cell therapy Yescarta has revealed genetic signatures of toxicity risk, potentially providing a path forward for…Fierce Biotech · 7d ago↗ source
- Lilly’s $3.8B psychedelics bet won’t open the M&A floodgatesEli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unl…